Physician profile
Robert Hoadley
NPI 1578007480
$4,988.28
in general payments reported to CMS, 2019-2025
19 companies · $15.64 in 2025
The $15.64 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $48.29 · 2022: $225 · 2023: $2,484 · 2024: $2,215 · 2025: $15.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,715.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,721.34 | 2022-2024 | Dovato, Cabenuva, Rukobia |
| Gilead Sciences, INC. | $1,096.05 | 2022-2025 | |
| Abbvie INC. | $452.03 | 2023-2024 | |
| Astrazeneca Pharmaceuticals Lp | $356.36 | 2023-2024 | Farxiga, Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $268.29 | 2022-2024 | Delstrigo, Dificid, Pifeltro |
| Janssen Scientific Affairs, LLC | $258.82 | 2023 | Symtuza |
| Janssen Biotech, INC. | $179.80 | 2022-2023 | Symtuza |
| Abbott Laboratories | $148.10 | 2021-2024 | Freestyle Libre 2, Proclaim |
| Lilly USA, LLC | $143.80 | 2023 | Mounjaro |
| Theratechnologies INC. | $92.85 | 2024 | Egrifta Sv |
| Emd Serono, INC. | $72.92 | 2023-2024 | Serostim |
| Pfizer INC. | $45.04 | 2023 | |
| Phadia US INC. | $40.48 | 2024 | Immunocap |
| Alnylam Pharmaceuticals INC. | $20.86 | 2023 | Givlaari |
| Verity Pharmaceuticals INC. | $18.99 | 2024 | Tlando |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $18.77 | 2024 | Ozempic, Rybelsus |
| Dynavax Technologies Corporation | $18.64 | 2023 | Heplisav-B |
| Sanofi-Aventis U.S. LLC | $17.59 | 2024 | |
| Amgen INC. | $17.55 | 2024 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hoadley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.